Current Open ResearchTrials


BOPP – Beta-blockers Or Placebo for Primary Prophylaxis of Oesophageal Varices. A blinded, UK multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial.

Re-opened 05/07/2021

Planned Recruitment end date: September 2022


ESSENCE – The Effect of Semaglutide in Non-cirrhotic, Non-alcoholic Steatohepatitis.

Site opened: 31/03/2021

Planned recruitment end date: 23/06/2023


MADRIGAL – A Phase 3, Multinational, Double-Blind, Randomised, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients with Non-alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation.

Site opened: 15/10/2019

Planned recruitment end date: 15/10/2019


MICAH – Multicentre Cohort Study in Alcoholic Hepatitis (in-patient trial)

Site opened: 30/09/2020

Planned recruitment end date: 30/11/2021


MIRAGE  - Pilot Randomised Trial of Functional Imagery Training Plus Treatment as Usual Versus Treatment As Usual Alone To Reduce Alcohol-Related Harm in Patients With Alcohol-Related Liver Disease Admitted To Hospital

Site opened: 19/04/2021

Planned recruitment end date: 30/09/2022


Pro Euro DILI – Prospective European DILI registry: Creation of a multicentre and Multidisciplinary European Registry of Prospective Drug-induced Liver Injury Cases

Site opened: 05/09/2017

Planned recruitment end date: 01/04/2022


TAK-242 – a Randomised, Double-blind, Placebo-controlled, Multicentre, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety Pharmacokinetics and Pharmacodynamics of Intravenous TAK-242 in Subjects With Acute Alcoholic Hepatitis Causing Decompensation of Alcohol-related Cirrhosis and Acute-on-Chronic Liver Failure

Site opened: 09/11/2020

Planned recruitment end date: 05/02/2022


UK-PBC – Investigation of the Genetic and Molecular Pathogenesis of Primary Biliary Cirrhosis Registry.

Site opened: 09/07/2008

Planned recruitment end date: 31/08/2021


UK-PSC – A UK Collaborative Study to Determine the Genetic Basis of Primary Sclerosing Cholangitis.

Site opened: 04/03/2009

Planned recruitment end date: 01/07/2023


GENFIT ELATIVE – A Double-blind, Randomized, Placebo-controlled Study and Open-Label Long Term Extension To Evaluate the Efficacy and Safety of Elafibranor 80mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Site opened: 13/08/2021

Planned recruitment end date: tbc


CYMABAY ASSURE – An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Site opened: 23/09/2021

Planned recruitment end date: 30/11/2022


SPRING – A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis

Site opened: 19/10/2021

Planned recruitment end date: tbc

Was this page helpful?

Was this page helpful?

Please answer the question below, this helps us to reduce the number of spam emails that we receive so that we can spend more time responding to genuine enquiries and feedback. Thank you.